By 2030, more than half of newly approved medicines are expected to incorporate AI in their discovery and development. Eli Lilly is leveraging its repository of over 200 clinical trial data sets and has formed a joint AI innovation lab with Nvidia. The collaboration includes construction of an AI supercomputer powered by Nvidia’s HGX H100 GPUs, designed to run large-scale molecular simulations and accelerate target identification. Lilly’s data science teams anticipate reducing lead compound identification timelines by up to 40%, potentially cutting R&D costs by hundreds of millions annually.

Eli Lilly and Repertoire Immune Medicines have entered a collaboration worth up to $1.93 billion, focused on discovering therapies for multiple autoimmune diseases. The multi-year agreement grants Lilly options to license Repertoire’s single-cell immune profiling platform and proprietary antibody libraries. In exchange, Lilly will fund research activities and milestone payments, with the first tranche of $150 million delivered upon initiation. Successful candidates could enter clinical testing as early as 2027, bolstering Lilly’s late-stage pipeline in rheumatoid arthritis, lupus and inflammatory bowel disease.

Lilly has signed a global research and licensing deal with Seamless Therapeutics to develop programmable recombinase–based treatments targeting genetic hearing loss. Seamless will receive over $1.12 billion in upfront and research funding plus potential biobucks for developmental and commercial milestones. The agreement grants Lilly exclusive rights to advance site-specific recombinases—capable of inserting large DNA segments independent of endogenous repair—through preclinical and clinical stages. Preclinical models have shown up to 80% correction of mutant alleles in cochlear cell lines, positioning Lilly to enter first-in-human trials by late 2027.

Eli Lilly has posted five consecutive quarterly earnings beats, driven by robust growth in diabetes and obesity franchises. Analysts project core operating margins north of 35% this year, supported by price discipline and volume gains in GLP-1 therapies. With over 10 late-stage assets—including two Alzheimer’s candidates—due to report phase III data by Q4, Lilly combines a solid balance sheet with R&D productivity that has delivered an average of two new molecular entities annually over the past five years. This track record underpins consensus expectations for 12% revenue growth in fiscal 2026.